Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR

Bone Marrow Transplantation

Volumn 48, Issue 1, 2013, Pages 56-62

  Imahashi, N ^a,b   Suzuki, R ^b   Fukuda, T ^c   Kakihana, K ^d   Kanamori, H ^e   Eto, T ^f   Mori, T ^g   Kobayashi, N ^h   Iwato, K ⁱ   Sakura, T ^j   Ikegame, K ^k   M Kurokawa, ^l   Kondo, T ^m   Iida, H ⁿ   Sakamaki, H ^d   Tanaka, J ^o   Kawa, K ^p   Morishima, Y ^q   Atsuta, Y ^b   K Miyamura, ^a  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e KANAGAWA CANCER CENTER   (Japan)

^f HAMANOMACHI HOSPITAL   (Japan)

^g KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h SAPPORO HOKUYU HOSPITAL   (Japan)

ⁱ ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^j SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^k HYOGO COLLEGE OF MEDICINE   (Japan)

^l UNIVERSITY OF TOKYO   (Japan)

^m KYOTO UNIVERSITY   (Japan)

ⁿ Meitetsu Hospital   (Japan)

^o HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^p RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^q AICHI CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

Allogeneic hematopoietic SCT; AML; First CR

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOGENETICS; DISEASE SEVERITY; DONOR SELECTION; FEMALE; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE STEM CELL TRANSPLANTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AGE FACTORS; BLOOD DONORS; BONE MARROW TRANSPLANTATION; CHROMOSOME ABERRATIONS; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; SIBLINGS; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84872123279     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.84     Document Type: Article

References (29)

1. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333. (Pubitemid 28452973)
2. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
3. Ringden O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D et al. The graftversus-leukemia effect using matched unrelated donors is not superior to HLAidentical siblings for hematopoietic stem cell transplantation. Blood 2009; 113: 3110-3118.
4. Rowe JM. Optimal induction and post-remission therapy for AML in first remission. Hematol Am Soc Hematol Educ Program 2009 396-405.
5. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301: 2349-2361.
6. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLAidentical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109: 3658-3666. (Pubitemid 46641712)
7. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102: 1232-1240. (Pubitemid 36988027)
8. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 2010; 115: 453-474.
9. Schlenk RF, Dohner K, Mack S, Stoppel M, Kiraly F, Gotze K et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 2010; 28: 4642-4648.
10. Gupta V, Tallman MS, He W, Logan BR, Copelan E, Gale RP et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010; 116: 1839-1848.
11. Walter RB, Pagel JM, Gooley TA, Petersdorf EW, Sorror ML, Woolfrey AE et al. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia 2010; 24: 1276-1282.
12. Schetelig J, Bornhauser M, Schmid C, Hertenstein B, Schwerdtfeger R, Martin H et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008; 26: 5183-5191.
13. Moore J, Nivison-Smith I, Goh K, Ma D, Bradstock K, Szer J et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007; 13: 601-607. (Pubitemid 46585933)
14. Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol 2007; 86: 269-274. (Pubitemid 350085818)
15. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
16. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276. (Pubitemid 11174888)
17. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706. (Pubitemid 29126745)
18. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007; 40: 381-387. (Pubitemid 47202424)
19. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. Highresolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-4583. (Pubitemid 351377826)
20. Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLAmatched, related hematopoietic stem cell transplants. Blood 2004; 103: 347-352. (Pubitemid 38029959)
21. Stern M, Brand R, de Witte T, Sureda A, Rocha V, Passweg J et al. Female-versusmale alloreactivity as a model for minor histocompatibility antigens in hematopoietic stem cell transplantation. Am J Transplant 2008; 8: 2149-2157.
22. Nannya Y, Kataoka K, Hangaishi A, Imai Y, Takahashi T, Kurokawa M. The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk. Transpl Int 2011; 24: 469-476.
23. Oh H, Loberiza Jr FR, Zhang MJ, Ringden O, Akiyama H, Asai T et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood 2005; 105: 1408-1416. (Pubitemid 40223655)
24. Kurosawa S, Yamaguchi T, Uchida N, Miyawaki S, Usuki K, Watanabe M et al. Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission. Biol Blood Marrow Transplant 2011; 17: 401-411.
25. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385-400. (Pubitemid 34994639)
26. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857-864. (Pubitemid 38970585)
27. Russell JA, Duan Q, Chaudhry MA, Savoie ML, Balogh A, Turner AR et al. Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease. Biol Blood Marrow Transplant 2008; 14: 888-895. (Pubitemid 351985026)
28. Bonetti F, Zecca M, Pession A, Messina C, Montagna D, Lanino E et al. Total-body irradiation and melphalan is a safe and effective conditioning regimen for autologous bone marrow transplantation in children with acute myeloid leukemia in first remission. The Italian Association for Pediatric Hematology and Oncology-Bone Marrow Transplantation Group. J Clin Oncol 1999; 17: 3729-3735.
29. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918. (Pubitemid 351620111)